He Gu, Chunyan Li, Jie Liang, Feng Tian, Xiaocang Cao, Yue Li, Yubei Gu, Jun Shen
{"title":"Clinical profiles and management strategies in older adults with mild-to-moderate ulcerative colitis: a multicenter, comparative, real-world study.","authors":"He Gu, Chunyan Li, Jie Liang, Feng Tian, Xiaocang Cao, Yue Li, Yubei Gu, Jun Shen","doi":"10.5217/ir.2026.00083","DOIUrl":"https://doi.org/10.5217/ir.2026.00083","url":null,"abstract":"<p><strong>Background/aims: </strong>The growing prevalence of mild-to-moderate ulcerative colitis (UC) among elderly individuals ( ≥60 years) poses unique clinical challenges due to age-related vulnerabilities, while real-world evidence on outpatient management and age-based differences remains limited.</p><p><strong>Methods: </strong>This multicenter cross-sectional study recruited 429 patients with mild-to-moderate UC from 47 inflammatory bowel disease centers. A Delphi-developed questionnaire was applied to assess clinical profiles and medication adherence. All statistical analyses were performed using R 4.5.0, with P-value < 0.05 set as the significance level.</p><p><strong>Results: </strong>Older patients had a longer median disease duration (6.0 years vs. 4.0 years; P= 0.001) and a higher proportion with moderate disease activity (60.4% vs. 51.8%; P= 0.029) compared with non-older patients. Diagnostic efficiency, disease extent, and extraintestinal manifestations did not differ between groups. Use of 5-aminosalicylic acid (5-ASA) remained the first-line therapy in both groups, with lower corticosteroid use among older patients (8.8% vs. 16.2%; P= 0.035). Older patients reported higher satisfaction with 5-ASA across several care domains (P= 0.019). Medication adherence was similar across age groups, and adherence analysis identified switching to biologics (odds ratio [OR], 0.31; P= 0.001), 3-4 physician visits for diagnosis (OR, 0.60; P= 0.048), and greater long-term efficacy satisfaction (OR, 0.64; P= 0.049) were associated with better adherence.</p><p><strong>Conclusions: </strong>Older adults with mild-to-moderate UC demonstrate distinct clinical phenotypes and divergent treatment priorities. Timely therapeutic escalation, the diagnostic process, and perceived treatment effectiveness are closely associated with medication adherence. These findings highlight the need for age-adapted management strategies in elderly UC patients.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comments on \"Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn's disease\".","authors":"Longwei Qiu, Junyi Tang, Chaochi Yue","doi":"10.5217/ir.2026.00236","DOIUrl":"https://doi.org/10.5217/ir.2026.00236","url":null,"abstract":"","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyuk Yoon, Sang Bum Kang, Seong-Joon Koh, Chang Kyun Lee, Dongwoo Kim, Eun Soo Kim, Sung Noh Hong, Dong Hyun Kim, Jin Wook Lee, Soo Jung Park, Chang Hwan Choi, Byung Ik Jang, Eun Mi Song, Soo-Kyung Park, Youngdoe Kim, Jong Min Choi, Su Young Jung, YoungJa Lee, Sang Hyoung Park
{"title":"Disease characteristics, outcomes, and poor prognostic factors of perianal fistula in Korean patients with Crohn's disease: a multicenter, retrospective observational study.","authors":"Hyuk Yoon, Sang Bum Kang, Seong-Joon Koh, Chang Kyun Lee, Dongwoo Kim, Eun Soo Kim, Sung Noh Hong, Dong Hyun Kim, Jin Wook Lee, Soo Jung Park, Chang Hwan Choi, Byung Ik Jang, Eun Mi Song, Soo-Kyung Park, Youngdoe Kim, Jong Min Choi, Su Young Jung, YoungJa Lee, Sang Hyoung Park","doi":"10.5217/ir.2026.00036","DOIUrl":"https://doi.org/10.5217/ir.2026.00036","url":null,"abstract":"<p><strong>Background/aims: </strong>A high proportion (39%-50%) of Korean patients with Crohn's disease (CD) suffer from perianal fistula, and real-world data on clinical practice remain limited. This study aimed to identify characteristics of perianal fistulizing CD (pfCD), treatment patterns, disease outcomes, and factors associated with poor prognosis in clinical practice in Korea.</p><p><strong>Methods: </strong>This was a multicenter, retrospective, observational study using chart reviews and clinical assessment of adult patients with pfCD from 15 medical centers. Patients were aged ≥ 19 years and had been treated for a newly diagnosed perianal fistula after January 1, 2011, with ≥ 1 year of follow-up. At enrollment, patient demographics, characteristics, treatments, and clinical outcomes were assessed.</p><p><strong>Results: </strong>Between September 2022 and August 2023, 487 patients met the inclusion criteria. Median age at initial diagnosis of perianal fistula was 21.7 years; 65.1% of patients had complex pfCD and 26.5% had multiple fistulas. Most patients (62.4%) had fistula-related surgical intervention (minor: 90.8%, 276/304; major: 22.4%, 68/304). Fistula recurrence was common (36.8%); median time to recurrence was 0.9 years (range, 0.01-10.8 years). Complications of perianal fistula including abscess (hazard ratio [HR], 1.67) and stricture (HR, 3.23), and fistula-related surgical intervention during the recurrence period (HR, 1.50) were positively associated and use of biologics (HR, 0.38) was negatively associated with recurrence events.</p><p><strong>Conclusions: </strong>This study highlights the high burden of disease, with most patients receiving multiple treatments and over one-third experiencing fistula recurrence. Biologics may be associated with lower risk of fistula recurrences.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Computed tomography enterography-defined transmural healing is associated with lower hospitalization risk in patients with Crohn's disease.","authors":"Yuki Yoshimatsu, Shinichi Hashimoto, Masahiro Tanabe, Satoko Matsumoto, Shunsuke Ito, Atsushi Goto, Koichi Hamabe, Jun Nishikawa, Katsuyoshi Ito, Taro Takami","doi":"10.5217/ir.2026.00113","DOIUrl":"https://doi.org/10.5217/ir.2026.00113","url":null,"abstract":"<p><strong>Background/aims: </strong>Transmural healing (TH) has emerged as a potential therapeutic target in Crohn's disease because transmural inflammation may persist despite clinical or endoscopic remission. However, evidence linking TH assessed by computed tomography enterography (CTE) to long-term outcomes remains limited. This study evaluated the association between TH assessed by low-dose CTE and long-term clinical outcomes.</p><p><strong>Methods: </strong>We performed a post hoc analysis of a previously reported retrospective cohort of patients with Crohn's disease who underwent low-dose CTE. Patients in clinical remission (Crohn's Disease Activity Index < 150) at the time of CTE and with ≥ 2 years of follow-up were included. TH was defined according to predefined imaging criteria. The primary outcome was maintenance of clinical remission. Secondary outcomes included hospitalization, bowel obstruction, corticosteroid initiation or escalation, and bowel surgery. Time-to-event outcomes were analyzed using Kaplan-Meier methods and Cox proportional hazards models.</p><p><strong>Results: </strong>Fifty-two patients were included, and 10 (19.2%) achieved TH. Prior bowel surgery was more common in the TH group (80.0% vs. 40.5%; P=0.040). During a mean follow-up of 83.1 months, Kaplan-Meier analyses showed significantly higher remission maintenance and lower hospitalization rates in the TH group (P=0.007 and P=0.013, respectively). In multivariable Cox analyses, TH remained independently associated with lower hospitalization risk (hazard ratio, 0.084; 95% confidence interval, 0.010-0.728; P=0.025), but not with clinical relapse.</p><p><strong>Conclusions: </strong>CTE-defined TH was independently associated with lower hospitalization risk, but not with maintenance of clinical remission, in patients with Crohn's disease; however, this association may have been influenced by prior bowel surgery.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Trends and safety of small bowel endoscopy in Crohn's disease in Japan: a large-scale claims database analysis.","authors":"Shuhei Hosomi, Yu Nishida, Tsuyoshi Yanagida, Koji Fujimoto, Rieko Nakata, Akinari Sawada, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Yasuhiro Fujiwara","doi":"10.5217/ir.2026.00149","DOIUrl":"https://doi.org/10.5217/ir.2026.00149","url":null,"abstract":"<p><strong>Background/aims: </strong>Evidence on the population-level utilization and safety of balloon-assisted endoscopy (BAE) and small bowel capsule endoscopy (SBCE) for Crohn's disease in Japan is limited. We aimed to characterize trends in BAE, SBCE, and patency capsule examination, as well as adverse events (AEs).</p><p><strong>Methods: </strong>We analyzed the Medical Data Vision claims database. Annual utilization was assessed per patient-year for the complete calendar years 2009-2021. AEs were defined by claimsbased therapeutic interventions after procedures. The association between patency capsule examination and SBCE-related AEs was assessed using generalized estimating equations (GEE) adjusted for age, sex, and calendar year.</p><p><strong>Results: </strong>Among 19,881 eligible patients with Crohn's disease, 4,657 BAE and 2,679 SBCE procedures were identified. Modality switching was uncommon, with 83.9% of patients with ≥2 examinations (n =1,683) undergoing the same modality at the second examination. Utilization of both modalities increased over time, and patency capsule examination before SBCE increased from 2013 to 2021. SBCE-related AEs were rare in patients with patency capsule examination compared to those without patency capsule examination (0.88% vs. 1.47%). In the main GEE analysis, patency capsule examination was not independently associated with lower odds of SBCE-related AEs (adjusted odds ratio, 0.62; 95% confidence interval, 0.28-1.37; P= 0.235), with a similar result in sensitivity analyses.</p><p><strong>Conclusions: </strong>The use of BAE and SBCE has increased in Japan alongside the spread of patency capsule examination. SBCE-related AEs were uncommon overall and numerically less frequent when preceded by patency assessment.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Intestinal ultrasound in the assessment of complicated Crohn's disease: a comprehensive review.","authors":"Min Kyu Kim, Sung Wook Hwang","doi":"10.5217/ir.2026.00111","DOIUrl":"https://doi.org/10.5217/ir.2026.00111","url":null,"abstract":"<p><p>Crohn's disease (CD) frequently progresses to stricturing or penetrating behavior, which often necessitates surgical or interventional management. Accurate, real-time assessment of these complications is essential for optimizing therapeutic strategies. This review summarizes the current evidence on the utility of intestinal ultrasound (IUS) and its advanced modalities in diagnosing, characterizing, and monitoring complicated CD. As a noninvasive, radiation-free, and cost-effective point-of-care tool, IUS demonstrates high diagnostic accuracy for detecting intestinal strictures, comparable to computed tomography and magnetic resonance enterography, and its diagnostic performance can be further enhanced by the use of small intestine contrast ultrasonography (SICUS). While differentiating between inflammatory and fibrotic strictures remains a critical clinical challenge, advanced techniques such as contrast-enhanced ultrasound (CEUS) and elastography are actively being investigated for elucidating the nature of stricture, albeit with heterogeneous results to date. Recent standardization of sonographic criteria for strictures has been proposed, with further clinical validation highly anticipated. Furthermore, IUS exhibits strong diagnostic performance in detecting penetrating complications, including abscess and fistulas. The diagnostic yield for these lesions is significantly enhanced by SICUS, which utilizes luminal distension to better visualize extra-luminal tracts. Notably, CEUS plays an important role in distinguishing true avascular abscesses from phlegmons. In conclusion, IUS has established itself as a highly reliable imaging modality for the evaluation of complicated CD. The utility of IUS is expected to grow, driving further research and optimizing point-of-care management for complicated CD.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Upadacitinib and upadacitinib-vedolizumab combination therapy for refractory pediatric-onset inflammatory bowel disease.","authors":"Hirotaka Shimizu, Ichiro Takeuchi, Hiroshi Oue, Hiroaki To, Atsushi Tanioka, Rina Komorizono, Katsuhiro Arai","doi":"10.5217/ir.2026.00119","DOIUrl":"https://doi.org/10.5217/ir.2026.00119","url":null,"abstract":"<p><strong>Background/aims: </strong>To evaluate the efficacy and safety of upadacitinib in patients with highly refractory pediatric-onset inflammatory bowel disease (IBD) and to describe the outcomes of upadacitinib-vedolizumab combination therapy (UVCT) in treatment-refractory cases.</p><p><strong>Methods: </strong>This retrospective, single-center study included 18 patients (7 with ulcerative colitis, 6 with Crohn's disease, and 5 with very early-onset IBD) who received upadacitinib between November 2022 and November 2025. Five patients underwent UVCT. All patients had previously failed multiple therapies (median, 3 prior advanced therapies). The primary outcome was the upadacitinib continuation rate. The secondary outcomes included corticosteroid- and tacrolimusfree remission rates, safety profiles, and UVCT outcomes.</p><p><strong>Results: </strong>The median age at upadacitinib initiation was 13.0 years (range, 2.3-21.6 years). The 52-week continuation rate was 55.6%. Among patients who received corticosteroids at baseline, 50% achieved corticosteroid-free status by 6 months; all patients who received tacrolimus at baseline discontinued tacrolimus within 6 months. No serious adverse events attributable to upadacitinib were observed and no cases of herpes zoster reactivation occurred. Five patients with persistent corticosteroid/tacrolimus dependence underwent UVCT, 4 of whom achieved clinical remission with withdrawal of corticosteroids/tacrolimus, with endoscopic improvement confirmed in 3. One patient with very early-onset IBD required colectomy.</p><p><strong>Conclusions: </strong>Upadacitinib demonstrated acceptable efficacy and safety in patients with highly refractory pediatric-onset IBD. In this small subgroup, UVCT was associated with clinical remission in most patients (4/5), suggesting that it may warrant further investigation as a salvage strategy to avert surgery. Prospective, multicenter studies are needed to define the optimal positioning within pediatric-onset IBD treatment algorithms.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comments on \"Ustekinumab-induced Henoch-Schönlein purpura in Crohn's disease: a case report and literature review\".","authors":"Se Jin Park, Jae Il Shin","doi":"10.5217/ir.2026.00155","DOIUrl":"https://doi.org/10.5217/ir.2026.00155","url":null,"abstract":"","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intestinal ResearchPub Date : 2026-10-01Epub Date: 2025-11-19DOI: 10.5217/ir.2025.00043
Peter Vivian Acire, Stephanie C Brown, Andrew S Day
{"title":"The role of the Mediterranean diet in the management of inflammatory bowel disease: a narrative review.","authors":"Peter Vivian Acire, Stephanie C Brown, Andrew S Day","doi":"10.5217/ir.2025.00043","DOIUrl":"10.5217/ir.2025.00043","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is characterized by the presence of gastrointestinal inflammation, that in some individuals leads on to complications, including strictures. IBD can be associated with significant morbidity with disruption of daily activities. Although the precise cause of IBD is unknown, epidemiologic studies indicate that diet is one contributory factor. Furthermore, various specific nutritional interventions have roles in the management of IBD. While the contribution of the Mediterranean diet (MedDiet) to the development or management of IBD has not yet been clearly delineated, available data are generally supportive. The MedDiet includes the consumption of a pattern of particular foods, such as plentiful vegetables, fruit, seafood, and olive oil, along with lifestyle features. Adherence to a MedDiet is associated with enrichment of beneficial components of the intestinal microbiome and enhanced barrier function: outcomes that are likely beneficial to individuals with IBD. The focus of this review was to highlight the evidence for the MedDiet in the setting of IBD, whilst giving an overview of the underlying health impacts of the MedDiet and the putative mechanisms of this dietary approach.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":"688-710"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13740775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145549375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intestinal ResearchPub Date : 2026-10-01Epub Date: 2026-03-26DOI: 10.5217/ir.2025.00315
Yoojeong Seo, Jinho Jang, Jae-Il Park
{"title":"Biology and preclinical models of colorectal cancer metastasis.","authors":"Yoojeong Seo, Jinho Jang, Jae-Il Park","doi":"10.5217/ir.2025.00315","DOIUrl":"10.5217/ir.2025.00315","url":null,"abstract":"<p><p>Metastatic colorectal cancer (mCRC) is the principal cause of CRC-related mortality, yet the biology of mCRC remains only partly understood and challenging to interrogate experimentally. Despite recent progress in mapping recurrent genetic and epigenetic alterations and treatment responses of mCRC, these efforts provide limited insight into how heterogeneous primary tumors breach tissue barriers, survive in circulation, and colonize distant organs. In this review, we summarize current experimental systems for studying mCRC, including genetically engineered mouse models, carcinogen-induced and transplant models, and patient-derived organoid and xenograft platforms, and discuss how each captures or fails to capture key steps of the metastatic cascade and organ-specific microenvironments. We highlight practical obstacles to longitudinal sampling and quantitative readouts of metastatic burden, as well as conceptual gaps in modeling immune and stromal influences. Finally, we outline how emerging approaches, including single-cell and spatial transcriptomics, and advances in longitudinal tracking of metastatic burden could be combined into an integrated framework that more faithfully links mechanistic insight to clinical behavior and ultimately to metastasis-specific therapies.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":"635-654"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13740777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}